Winter Meeting 2011 - The Pathological Society of Great Britain ...

Foyer
08.00 Registration and Coffee
Detailed Programme – Thursday 6 January 2011
Presenter = P · Abstract numbers are shown in bold and square brackets eg [S123]
Rosalind Franklin Pavilion
09.00–18.00* Slide seminar competition Case viewing: The Partnership between Molecular and
Conventional Histopathology
* Note: Competition closes at 16.30.
Francis Crick Auditorium
09.00–12.00 Symposum: Molecular Pathology for Today and Tomorrow – 1
Chair: Prof VP Collins, University of Cambridge, Addenbrooke’s Hospital, Cambridge
Prof AL Børresen-Dale, Oslo University Hospital Radiumhospitalet, Oslo, Norway
09.00–09.15 Introduction
Prof AH Wyllie, University of Cambridge
09.15–09.45 The Lessons of GIST
Dr R Bulusu, Addenbrooke’s Hospital, Cambridge
09.45–10.30 [S1] Molecular Classification of Breast Cancer; A Systems Pathology Approach
P Prof AL Børresen-Dale
Oslo University Hospital Radiumhospitalet, Oslo, Norway
Microarray technologies, applied to the study of DNA/mRNA/miRNA, can be used to portray a tumour’s detailed
phenotype in its unique context, and to generate molecular signatures that will improve our understanding of the
causes and progression of the disease, for the discovery of new molecular markers, for therapeutic intervention and
for developing new prevention strategies.
Two platform independent algorithms were developed to explore genomic architectural distortion using aCGH
data to measure whole arm gains and losses (WAAI) and complex rearrangements (CAAI). By applying this to
>500 bc cases relationship between structural genomic alterations, expression subtypes and clinical behaviour could
be found.
Using SNP arrays and a novel bioinformatic approach, ASCAT, we could accurately dissect the allele-specific copy
number in each tumour, simultaneously estimating and adjusting for both tumour ploidy and non-aberrant cell
admixture. This enabled us to construct genome-wide map of allelic skewness, identifying loci where one allele is
preferentially lost/gained, indicating different influence on bc development. By integrating data from the patient’s
own genotype with data from the tumour at the DNA level, (copynumber, mutations, methylation), mRNA and
miRNA level as well as metabiloc profiles revealed from HR-MAS MR analyses of the tumour, we seek to reach a
more fundamental understanding of the biological dynamics of bc. This will facilitate identification of risk factors,
search for novel cancer diagnostics, prediction of therapeutic effects and prognosis and identification of new targets
for therapy. Perou C et al Nature 2000 Sorlie T et al PNAS, 2001 and 2003 Bergamaschi A et al GCC, 2006 Hicks J
et al. Gen. Res. 2006 Russnes H et al ScienceTM, 2010 Van Loo P et al PNAS, 2010.
10.30–11.00 Coffee / Poster Viewing / Trade Exhibition [Cloisters]
11.00–11.10 Welcome
From Sir L Borysiewicz, Vice-Chancellor, University of Cambridge
11.10–11.30 [S2] The Histopathologist and Breast Cancer Trials
P Dr E Provenzano
Addenbrooke’s Hospital, Cambridge, United Kingdom
Neoadjuvant therapy is being increasingly utilised in the treatment of patients with breast cancer. The neoadjuvant
setting provides an excellent opportunity for evaluation of response to newer chemotherapeutic and hormonal
agents with complete pathological response (pCR) acting as a surrogate outcome for disease free survival.
Neoadjuvant clinical trials can be used to answer both clinical and prospective translational molecular questions,
with detailed biological assessment of tumour tissue for molecular profiling, biomarker discovery and candidate
gene analysis. The accuracy of the results from these subsequent biomarker and molecular genetic analyses is
dependent upon thorough handling of the surgical specimen with the detection of any residual disease. Surgical
specimens post neoadjuvant therapy can be very difficult to handle, especially when there has been a good response
to therapy with no macroscopically detectable residual lesion. Accurate clinical details and correlation with
10 Visit our website: www.pathsoc.org | Winter Meeting (199 th ) 6 – 7 January 2011 | Scientific Programme